Next Article in Journal
Perceptions of Parents towards COVID-19 Vaccination in Children, Aseer Region, Southwestern Saudi Arabia
Previous Article in Journal
Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
 
 
Article

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine

1
The Infectious Diseases Unit, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel
2
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel
3
Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
4
Bio-statistical and Bio-mathematical Unit, The Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel
5
Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
6
Central Virology Laboratory, Ministry of Health and Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel
7
ARC Innovation Center, Tel Hashomer, Ramat Gan 52621, Israel
8
The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel
*
Author to whom correspondence should be addressed.
Academic Editors: Giuseppe La Torre and Ger Rijkers
Vaccines 2022, 10(8), 1220; https://doi.org/10.3390/vaccines10081220
Received: 20 June 2022 / Revised: 20 July 2022 / Accepted: 28 July 2022 / Published: 30 July 2022
Objectives: The BNT162b2 mRNA COVID-19 vaccine has been found to be highly effective in preventing COVID-19 but is associated with increased reactogenicity. We aimed to examine the correlation between immunogenicity and reactogenicity of the BNT162b2 vaccine. Methods: Subjects without prior SARS-CoV-2 infection that participated in active surveillance after being vaccinated with the BNT162b2 vaccine were included. Study participants reported adverse drug reactions (ADRs) through questionnaires administered by text message after receiving each dose of the vaccine. A reactogenicity score was developed based on the type and duration of ADRs. In addition, anti-receptor binding domain (RBD) levels and neutralization assays were performed 7–21 and 7–38 days after the first and second vaccine doses, respectively. Associations between ADRs and antibody levels were assessed by Spearman correlations. Multivariable logistic regression analyses were used to identify factors associated with ADRs. Results: A total of 831 health care workers were included. The mean age was 46.5 years (SD = 11.8) and 75.5% were females. 83.4% and 83.3% had at least one local ADR after the first and second doses, respectively. 33% and 83.2% had at least one systemic ADR after the first and second doses, respectively. Multivariate logistic regression analysis found a significant correlation between ADR score and anti-RBD-IgG titers (r = 0.366; p < 0.0001) after adjustment for age, gender, and days after the second vaccination. High anti-RBD-IgG levels, being younger than 55 and being female, were all correlated with increased rates of ADRs. Conclusion: BNT162b2 mRNA COVID-19 vaccine reactogenicity appears to be correlated with higher post-vaccination antibody levels and is independently associated with younger age and female gender. View Full-Text
Keywords: BNT162b2; immunogenicity; reactogenicity; COVID-19; vaccination BNT162b2; immunogenicity; reactogenicity; COVID-19; vaccination
Show Figures

Figure 1

MDPI and ACS Style

Levy, I.; Levin, E.G.; Olmer, L.; Regev-Yochay, G.; Agmon-Levin, N.; Wieder-Finesod, A.; Indenbaum, V.; Herzog, K.; Doolman, R.; Asraf, K.; Halperin, R.; Lustig, Y.; Rahav, G. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine. Vaccines 2022, 10, 1220. https://doi.org/10.3390/vaccines10081220

AMA Style

Levy I, Levin EG, Olmer L, Regev-Yochay G, Agmon-Levin N, Wieder-Finesod A, Indenbaum V, Herzog K, Doolman R, Asraf K, Halperin R, Lustig Y, Rahav G. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine. Vaccines. 2022; 10(8):1220. https://doi.org/10.3390/vaccines10081220

Chicago/Turabian Style

Levy, Itzchak, Einav Gal Levin, Liraz Olmer, Gili Regev-Yochay, Nancy Agmon-Levin, Anat Wieder-Finesod, Victoria Indenbaum, Karin Herzog, Ram Doolman, Keren Asraf, Rebecca Halperin, Yaniv Lustig, and Galia Rahav. 2022. "Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine" Vaccines 10, no. 8: 1220. https://doi.org/10.3390/vaccines10081220

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop